Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI (NCT06678074) | Clinical Trial Compass
Active — Not RecruitingPhase 1/2
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
United States10 participantsStarted 2025-02-06
Plain-language summary
Adults who have had an ST-elevation myocardial infarction and were treated with stent placement will receive an intravenous infusion of a monoclonal antibody in order to prevent further heart muscle damage. The goal is to learn if this treatment improves some measures of heart function and inflammation. The study treatment patients will be compared to patients who receive placebo (inactive treatment).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Acute myocardial infarction with ST elevation at the J-point in two contiguous leads as determined by ECG.
. TIMI grade 0 (no flow) or grade 1 (penetration without perfusion) of the culprit artery on initial coronary angiogram
. Symptom onset prior to PCI of ≤12 hours
. Planned to receive the local standard of care for treatment of their STEMI and follow up which must include percutaneous coronary intervention (PCI)
. Ability to infuse study drug within 12 hours of PCI
. Age ≥18 years, willing and able to provide written informed consent and to comply with the protocol (i.e., reporting of symptoms)
. Capable of completing study visits
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial is in Phase 1/2 and primarily measuring safety and tolerability of IC14 rather than whether it improves outcomes after a STEMI, what does that mean for what is — and isn't — known yet about whether this drug could actually help me?
2IC14 is an anti-CD14 monoclonal antibody, which means it targets part of the immune response — can you explain what risks that might carry for someone who just had a heart attack and had a stent placed, especially in terms of infection or healing?
3The trial is listed as active but no longer enrolling new patients — does that affect my options in any way, and are there similar or follow-on studies I might be eligible for instead?
4Given that I've just had a STEMI and a stent implanted, would you recommend focusing on established, standard-of-care treatments right now rather than an experimental therapy that is still in an early safety-testing phase?
5If I were able to discuss this trial with the research team, what questions would you want answered about how IC14 interacts with the other medications I'll be taking after my heart attack, like blood thinners or statins?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of treatment-emergent adverse events (safety and tolerability)